Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Bio-Techne Corp(TECH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TECH
09/25/2026: TECH (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Bio-Techne Corp is a specialized provider of life science reagents, analytical instruments, and clinical diagnostics, functioning primarily as a critical supplier to the biopharmaceutical and academic research markets. The company is known for its high-margin consumable business, particularly in protein research, which offers revenue stability. Its primary growth story revolves around its expansion into high-growth areas like spatial biology and cell therapy manufacturing. Investors must consider risks such as cyclical funding for research and intense competition from larger industry peers. Bio-Techne may best suit growth-oriented investors looking for exposure to the tools and infrastructure underpinning scientific innovation, with a focus on tracking R&D spend trends.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company targets high-growth segments like spatial biology and cell therapy manufacturing. |
| Momentum investor | Mixed fit | Momentum is conditional on a sustained upturn in biopharma R&D spending signals. |
| Value investor | Mixed fit | Valuation often trades at a premium due to high-quality growth expectations. |
| Dividend investor | Weak fit | Dividends are provided but are not the primary driver of total shareholder returns. |
| Low-risk investor | Mixed fit | While quality is high, equity volatility is inherent to the life sciences tools sector. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Biotech market sentiment can lead to rapid price swings. |
| Valuation risk | Medium | High P/E ratios can compress if growth slows. |
| Competition risk (Diversified Life Science Tools) | High | Large competitors like Thermo Fisher have superior scale. |
| Business quality | Strong | Strong recurring revenue from consumables provides a solid floor. |
| Dividend income | Low | Income is not a significant component of the investment thesis. |
| Execution risk | Medium | Successful integration of acquired technologies is critical. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -50.11% | Avg. Invested days 23 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 11.39B USD | Price to earnings Ratio 62.59 | 1Y Target Price 70.73 |
Price to earnings Ratio 62.59 | 1Y Target Price 70.73 | ||
Volume (30-day avg) 2.8M shares | Beta 1.27 | 52 Weeks Range 43.02 - 72.69 | Updated Date 09/27/2026 |
52 Weeks Range 43.02 - 72.69 | Updated Date 09/27/2026 | ||
Dividends yield (FY) 0.44% | Basic EPS (TTM) 1.16 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Protein Sciences | Cytokines, antibodies, and immunoassay kits. | The reliable core of the business that researchers buy daily. |
| Diagnostics and Genomics | Clinical controls, RNAscope, and spatial biology platforms. | Higher-growth segments focused on advanced clinical insights. |
| Geography | Sales across North America, Europe, and Asia-Pacific. | Global diversification buffers against regional funding shifts. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 62.59 | Forward PE 34.6 | Enterprise Value 11.40B | Price to Sales(TTM) 9.37 |
Enterprise Value 11.40B | Price to Sales(TTM) 9.37 | ||
Enterprise Value to Revenue 9.38 | Enterprise Value to EBITDA 32.79 | Shares Outstanding 156.82M | Shares Floating 156.16M |
Shares Outstanding 156.82M | Shares Floating 156.16M | ||
Percent Insiders 0.33 | Percent Institutions 115.12 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Bio-Techne Corp
Exchange NASDAQ | Headquarters Minneapolis, MN, United States | ||
IPO Launch date 1989-02-09 | CEO, President & Director Mr. Kim Kelderman | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3000 | Website https://www.bio-techne.com |
Full time employees 3000 | Website https://www.bio-techne.com | ||
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.